earnings
confidence high
sentiment positive
materiality 0.60
Vyome Q2 2026 net loss $0.7M; advances VT-1953 FDA plan, in-licenses JAK inhibitors
Vyome Holdings, Inc
2026-Q2 EPS
reported -$0.24
vs consensus -$0.19
▼ miss
(-23.8%)
- Net loss of $720K ($0.10/share) for Q2 2026; cash $7.9M vs $5.0M at Dec 31, 2025.
- Received FDA written response on VT-1953 pivotal study strategy; plans Type C meeting.
- In-licensed two selective JAK inhibitor assets from Impetis Biosciences for autoimmune conditions.
- Granted Chinese patent for VB-1953 topical gel formulation and therapeutic acne claims.
- Phase 2 VT-1953 data showed significant malodor/pain reductions with no treatment-emergent AEs.